言語を選択

TRAIL

TRAIL 詳細

英語名	Tumor necrosis factor ligand superfamily member 10	市販薬剤の数	0
治験薬の数	1	ターゲットの別称	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
研究＆開発段階	Phase 2 Clinical

英語名	Tumor necrosis factor ligand superfamily member 10
ターゲットの別称	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
市販薬剤の数	0
治験薬の数	1
研究＆開発段階	Phase 2 Clinical

TRAIL 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
Fc Tag (1)His Tag (1)
マーカー
Unconjugated (2)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
TRL-H5243	Human	HEK293	Human TRAIL / TNFSF10 Protein, His Tag, active trimer (MALS verified)
TRL-H5263	Human	HEK293	Human TRAIL / TNFSF10 Protein, Fc Tag, active trimer (MALS verified)

総数量2

TRAILバックグランド

TRAIL, also known as TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

TRAIL分子の別称

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
AS-1501	AS-1501	Phase 2 Clinical	Shenzhen Zhongke Amshenn Pharmaceutical Co Ltd	Acute-On-Chronic Liver Failure; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Hepatic Insufficiency; Hepatitis; Liver Failure; Myocardial Infarction; Reperfusion Injury	詳細